SCNI — Scinai Immunotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.60m
- $5.86m
- $1.31m
Annual income statement for Scinai Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 10-K | 20-F | 20-F | 20-F |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.658 | 1.31 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | -0.58 | -2.65 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 10.8 | 11.1 | 9.71 | -5.46 | 8.85 |
| Operating Profit | -10.8 | -11.1 | -9.71 | 6.12 | -7.54 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -12.4 | -5.8 | -6.5 | 4.8 | -8.31 |
| Net Income After Taxes | -12.4 | -5.8 | -6.5 | 4.8 | -8.31 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.4 | -5.8 | -6.5 | 4.8 | -8.31 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.4 | -5.8 | -6.5 | 4.8 | -8.31 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.19 | -0.008 | -0.042 | -0.003 | -0.001 |